Endotoxin induced uveitis
- An intravitreal (i.v.t.) injection of bacterial endotoxin (t=0) stimulates an influx of inflammatory cells, predominantly neutrophils, into the anterior uvea section of the eye.
- This model is sensitive to pre-treatment with steroid, both by topical ( t= -30 min, 1hr, 2hr, 4hr) and intravitreal dosing (t=-1hr).
- Uveitis, or intraocular inflammatory disease, is a damaging ocular condition which can cause cataracts, glaucoma, macular oedema, and eventually blindness.
- It is estimated that the incidence of visual loss due to uveitis is on a par with that of diabetes, and is the cause of 10-15% of all total blindness in the United States.
- Current therapies for uveitis, and many other chronic inflammatory disorders such as asthma, are steroids, immunosuppressive agents and non-steroidal anti-inflammatories (NSAIDS).
- These drugs do not completely control the disease processes and are not well tolerated due to the development of multiple adverse effects, and length of duration of treatment.
- Approximately 3-4 weeks
- Total cell counts in the aqueous humor (fluid between the lens and the cornea of the eye)
- Cytokine analysis of the anterior/posterior eye homogenate
- Histological assessment of cellular infiltration
Intravitreal (I.v.t.) administration of LPS induces a significant increase in the number of total inflammatory cells recruited into the aqueous humor, which is reduced following single dose of i.v.t. dexamethasone.
Intravitreal (I.v.t.) administration of LPS induces an increase in IL-1B and MCP-1 levels in the anterior uvea, which is reduced following single dose of i.v.t. administered dexamethasone.
Intravitreal (I.v.t.) administration of LPS induces an increase in IL-1B and MCP-1 levels in the anterior uvea, which is reduced following multiple doses of topical dexamethasone.
# compared to control, * compared to LPS